Henk Codrington

782 citations

20 papers · 587 indexed · h-index 11

Pulmonary and Respiratory Medicine top 5%
Oncology top 10%
Radiology, Nuclear Medicine and Imaging top 10%
Surgery
Molecular Biology

Co-authors: Joachim G.J.V. Aerts Renato A. Valdés Olmos Renée van Pel Houke M. Klomp Harm van Tinteren Ingrid Kappers Tom G. Sutedja Pieter E. Postmus
Topics: Lung Cancer Treatments and Mutations (12 papers)Lung Cancer Diagnosis and Treatment (9 papers)Colorectal Cancer Treatments and Studies (6 papers)
Cited by: Geriatrics and Gerontology Pulmonary and Respiratory Medicine Oncology
Journals: Journal of Clinical Oncology CHEST Journal Annals of Oncology
Partner nations: Netherlands United States Malaysia

In The Last Decade

Henk Codrington

20 papers receiving 575 citations

Peers

Countries citing papers authored by Henk Codrington

Since Specialization

Citations

This map shows the geographic impact of Henk Codrington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henk Codrington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henk Codrington more than expected).

Fields of papers citing papers by Henk Codrington

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henk Codrington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henk Codrington. The network helps show where Henk Codrington may publish in the future.

Co-authorship network of co-authors of Henk Codrington

This figure shows the co-authorship network connecting the top 25 collaborators of Henk Codrington. A scholar is included among the top collaborators of Henk Codrington based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henk Codrington. Henk Codrington is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer 2023 ·BMC Cancer ·(unknown),J. Zwaveling,(unknown),(unknown),Johanneke E.A. Portielje,Henk Codrington,(unknown),Pepijn Brocken,Egbert F. Smit,Loes E. Visser	7
2	Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study 2022 ·Journal of Geriatric Oncology ·(unknown),(unknown),Erik B. Wilms,Pepijn Brocken,Henk Codrington,Danny Houtsma,Johanneke E. A. Portielje,Nienke A. de Glas,(unknown),Frederiek van den Bos,Loes E. Visser	6
3	The Effect of A Geriatric Assessment on Treatment Decisions for Patients with Lung Cancer 2017 ·Lung ·(unknown),Esteban T.D. Souwer,Marije E. Hamaker,Henk Codrington,Simone van der Sar–van der Brugge,Jan‐Willem J. Lammers,Johanneke E.A. Portielje,Leontine J. R. van Elden,Frederiek van den Bos	32
4	Prognostic Value of Geriatric 8 and Identification of Seniors at Risk for Hospitalized Patients Screening Tools for Patients With Lung Cancer 2017 ·Clinical Lung Cancer ·(unknown),Esteban T.D. Souwer,Leontine J. R. van Elden,Henk Codrington,Simone van der Sar–van der Brugge,Jan‐Willem J. Lammers,Johanneke E.A. Portielje,Frederiek van den Bos,Marije E. Hamaker	34
5	Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab 2016 ·Radiotherapy and Oncology ·Iris Walraven,Michel M. van den Heuvel,Judi van Diessen,Eva Schaake,Wilma Uyterlinde,Joachim G.J.V. Aerts,(unknown),Henk Codrington,Peter W.A. Kunst,Edith Dieleman,(unknown),Marcel Verheij,J. Belderbos	54
6	Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non–Small-Cell Lung Cancer 2016 ·Journal of Clinical Oncology ·Roelof W. F. van Leeuwen,(unknown),Koen G. A. M. Hussaarts,(unknown),Nikki S. IJzerman,Peter de Bruijn,Cor van der Leest,Henk Codrington,Jeroen S. Kloover,Bronno van der Holt,Joachim G.J.V. Aerts,Teun van Gelder,Ron H.J. Mathijssen	94
7	18F-Fluorodeoxyglucose Positron Emission Tomography versus Computed Tomography in Predicting Histopathological Response to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor Treatment in Resectable Non-Small Cell Lung Cancer 2014 ·Annals of Surgical Oncology ·(unknown),Tjeerd S. Aukema,Eva E. Schaake,Herman Rijna,Henk Codrington,Renato A. Valdés Olmos,Hendrik J. Teertstra,Renée van Pel,Sjaak A. Burgers,Harm van Tinteren,Houke M. Klomp	24
8	A randomized phase II study of paclitaxel-carboplatin-bevacizumab (PCB) with or without nitroglycerin patches (NTG) in patients (pts) with stage IV nonsquamous non-small cell lung cancer (NSCLC): Nvalt 12 (NCT01171170). 2014 ·Journal of Clinical Oncology ·Anne‐Marie C. Dingemans,Harry J.M. Groen,(unknown),Jos A. Stigt,Egbert F. Smit,Idris Bahce,Otilia Dalesio,Sjaak A. Burgers,Henk Codrington,Ben van den Borne,Bonne Biesma,Andrew Vincent,(unknown),Joachim G.J.V. Aerts	2
9	Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multi-center phase II study investigating 2013 ·Radiotherapy and Oncology ·Michel M. van den Heuvel,Wilma Uyterlinde,Andrew Vincent,Jeroen de Jong,Joachim G.J.V. Aerts,(unknown),J. Knegjens,Henk Codrington,(unknown),Edith Dieleman,Marcel Verheij,J. Belderbos	40
10	A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study 2013 ·Annals of Oncology ·Joachim G.J.V. Aerts,Henk Codrington,Nienke A. G. Lankheet,Sjaak A. Burgers,Bonne Biesma,Anne‐Marie C. Dingemans,Andrew Vincent,(unknown),Harry J.M. Groen,Egbert F. Smit	40
11	Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non–Small-Cell Lung Cancer 2012 ·Journal of Clinical Oncology ·Eva E. Schaake,Ingrid Kappers,Henk Codrington,Renato A. Valdés Olmos,Hendrik J. Teertstra,Renée van Pel,Jacobus A. Burgers,Harm van Tinteren,Houke M. Klomp	68
12	A randomized, multicenter phase II study investigating additional weekly cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Reporting on the efficacy. 2012 ·Journal of Clinical Oncology ·Michel M. van den Heuvel,Andrew Vincent,Wilma Uyterlinde,Joachim G.J.V. Aerts,(unknown),Henk Codrington,(unknown),Edith Dieleman,(unknown),Marcel Verheij,J. Belderbos	5
13	A Randomized Phase II Study Comparing Erlotinib (E) Versus e Alternating with Chemotherapy in Relapsed Non-Small Cell Lung Cancer (NSCLC) Patients. The NVALT10 Study 2012 ·Annals of Oncology ·(unknown),Henk Codrington,Sjaak A. Burgers,Bonne Biesma,Otilia Dalesio,Anne‐Marie C. Dingemans,Andrew Vincent,Harry J.M. Groen,Egbert F. Smit	2
14	OC-0498 CONCURRENT CHEMORADIOTHERAPY WITH OR WITHOUT CETUXIMAB IN NSCLC; TOXICITY RESULTS OF A RANDOMIZED PHASE II TRIAL 2012 ·Radiotherapy and Oncology ·J. Belderbos,Wilma Uyterlinde,(unknown),(unknown),Henk Codrington,(unknown),Peter W.A. Kunst,Edith Dieleman,Marcel Verheij,Michel M. van den Heuvel	2
15	Is ¹⁸F-FDG PET/CT Useful for the Early Prediction of Histopathologic Response to Neoadjuvant Erlotinib in Patients with Non–Small Cell Lung Cancer? 2010 ·Journal of Nuclear Medicine ·Tjeerd S. Aukema,Ingrid Kappers,Renato A. Valdés Olmos,Henk Codrington,Harm van Tinteren,Renée van Pel,Houke M. Klomp,(unknown)	66
16	Prevention of anaemia by early intervention with once weekly epoetin alfa during chemotherapy 2008 ·European Journal of Cancer ·J.H. Schouwink,Henk Codrington,H.P. Sleeboom,(unknown),Lars W. Wormhoudt	7
17	Unusual Pulmonary Lesions 2002 ·Journal of Clinical Oncology ·Henk Codrington,Tom G. Sutedja,Richard P. Golding,(unknown),Elle K.J. Risse,Pieter E. Postmus	2
18	Autofluorescence Bronchoscopy Improves Staging of Radiographically Occult Lung Cancer and Has an Impact on Therapeutic Strategy 2001 ·CHEST Journal ·Tom G. Sutedja,Henk Codrington,Elle K.J. Risse,R.H.J. Breuer,Johan C. van Mourik,Richard P. Golding,Pieter E. Postmus	73
19	Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer 2001 ·Lung Cancer ·John W.G. van Putten,Paul Baas,Henk Codrington,(unknown),Martín Müller,Neil K. Aaronson,Harry J.M. Groen	28
20	Second-line treatment with single-agent gemcitabine (GEM) in patients (PTS) with advanced non-small-cell lung cancer (NSCLC) 2000 ·Lung Cancer ·J.W.G. van Putten,Paul Baas,Henk Codrington,(unknown),Harry J.M. Groen	1

About Henk Codrington

Henk Codrington is a scholar working on Geriatrics and Gerontology, Pulmonary and Respiratory Medicine and Oncology, having authored 20 papers that have together received 587 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Colorectal Cancer Treatments and Studies (6 papers). The work is most often cited by research in Geriatrics and Gerontology (54 citations), Pulmonary and Respiratory Medicine (439 citations) and Oncology (236 citations). Henk Codrington has collaborated with scholars based in Netherlands, United States and Malaysia. Frequent co-authors include Joachim G.J.V. Aerts, Renato A. Valdés Olmos, Renée van Pel, Houke M. Klomp, Harm van Tinteren, Ingrid Kappers, Tom G. Sutedja, Pieter E. Postmus, Richard P. Golding and Elle K.J. Risse. Their work appears in journals such as Journal of Clinical Oncology, CHEST Journal and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact